Advances in Influenza Treatment: Optimizing Outcomes in High-Risk Influenza Patients with Chronic Cardiometabolic Conditions

Despite advances in understanding, prevention, and treatment, influenza is still associated with a constant public health concern. Moreover, in patients with chronic conditions, including those with diabetes, cardiovascular disease, renal impairment, or with cardiometabolic risk factors (obesity, tobacco users), influenza can often lead to severe or even fatal disease. Vaccination against the influenza virus is one of the most effective ways to decrease the impact of influenza in individuals with the cardiometabolic disease but due to frequent viral shifts, existing vaccines may be rendered ineffective and new vaccine formulations are only available after the emergence and spread of an existing influenza pandemic, which significantly decreases their utility. Furthermore, the effectiveness of influenza vaccines is reduced in elderly individuals (who usually have a high cardiometabolic burden) and in those with diabetes or other chronic health conditions.

Given that patients with diabetes, heart disease, obesity, or other cardiometabolic risk factors are at a high-risk for developing flu-related complications, it is important for clinicians that care for these patients to be aware of the impact of influenza. This webinar, led by 3 experts in the field, will address the latest evidence in influenza treatment and management of patients with chronic cardiometabolic health conditions.

AGENDA

Influenza Update: Prevalence, Transmission, Impact, and Prevention

Gregory A. Poland, MD, MACP, FRCP

Influenza and Its Consequences

Stefan Gravenstein, MD, MPH

Update on Influenza: Treatment

Michael G. Ison, MD, MS, FIDSA, FAST

Patient Case and Panel Discussion

Case Presenter:
Michael G. Ison, MD, MS, FIDSA, FAST

Panel:
Stefan Gravenstein, MD, MPH; Gregory A. Poland, MD, MACP, FRCP

Audience Q&A and Conclusions

All Faculty

Target Audience

This activity is designed for US-based endocrinologists, cardiologists, physician assistants, registered nurses, nurse practitioners, and pharmacists.

Learning Objectives

  • Summarize the influenza life cycle and the clinical impacts of influenza in patients with chronic cardiometabolic conditions
  • Interpret existing and new evidence with traditional and new influenza treatments for high-risk patients, including differences in efficacy, safety, and mechanisms of action
  • Identify approaches to reducing the burden of influenza in cardiometabolic patients, including prompt treatment with antivirals or referrals.
Course summary
Available credit: 
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Course opens: 
06/12/2020
Course expires: 
06/12/2021
Rating: 
0

Stefan Gravenstein, MD, MPH

Stefan Gravenstein, MD, MPH

  • Director of the Division of Geriatrics and Palliative Medicine
  • Department of Medicine
  • Warren Alpert Medical School of Brown University
  • Providence, RI

Michael G. Ison, MD, MS, FIDSA, FAST

Michael G. Ison, MD, MS, FIDSA, FAST

  • Division of Infectious Diseases and Organ Transplantation
  • Transplant & Immunocompromised Host Infectious Diseases Service
  • Northwestern University Comprehensive Transplant Center
  • Chicago, IL

Gregory A. Poland, MD, MACP, FRCP

Gregory A. Poland, MD, MACP, FRCP

  • Mary Lowell Leary Emeritus Professor of Medicine
  • Distinguished Investigator, Mayo Clinic
  • Director, Mayo Vaccine Research Group
  • Editor-in-Chief, VACCINE
  • Mayo Clinic
  • Rochester, MN

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Genentech, a member of the Roche Group.

JOINT ACCREDITATION STATEMENT

image image image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

PHARMACIST ACCREDITATION STATEMENT

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-20-2150-H01-P

Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Dr. Gravenstein discloses the following:

  • Consulting Fees: Janssen, Seqirus, Sanofi
  • Contracted Research: Seqirus, Sanofi, Pfizer

Dr. Ison discloses the following:

  • Research Support (Paid to Northwestern University): AiCuris, Genentech/Roche, Janssen, Shire
  • Paid Consultation (Paid to Michael Ison): AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
  • Unpaid Consultation: GlaxoSmithKlein, Romark, Vertex
  • Data and Safety Monitoring Board Participation: NIH, Janssen, Merck, Vitaeris

Dr. Poland discloses the following:
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Sanofi Pasteur, GlaxoSmithKline, Emergent Biosolutions, Medicago, and Dynavax. Dr. Poland holds two patents related to vaccinia and measles peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.

Planners and Managers

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period June 12, 2020 through June 12, 2021, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be emailed. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome hereFirefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.